Orally Delivered CRISPR Therapy, Groundbreaking Evolution
/0 Comments/in CRISPR, Not PCa related, Preclinical Research/by Max225Ac-Macropa-PEG4-YS5: a CD46-Targeted 225Ac Therapy for Prostate Cancer
/0 Comments/in Preclinical Research/by MaxNext-Generation ADCs for Cancer Treatment with Potential in Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 16/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! I hope this collection of very promising clinical and preclinical research makes a nice Easter gift for you. Wishing you all a warm hug and a Happy Easter! Stay strong and fight on! As usual, we also have a podcast if […]
Phase1/2: Kesonotide For Metastatic Castration-Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1 Trial: GEN1057 Bispecific-Antibody In Metastatic Solid Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxCD-001: A Promising Novel Dual-Targeting Immunotherapy
/0 Comments/in Immunotherapy, Preclinical Research/by MaxSDV2102: A Promising ADC That Targets PSMA Expressing Tumors
/0 Comments/in Antibody-Drug Conjugate, Preclinical Research/by MaxBTE-EN1: Some Hope For Prostate Cancer Patients with Bone Metastasis
/0 Comments/in Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- MDNA113 a Potentially Groundbreaking Immune Therapy for Solid Tumors Including mCRPC June 30, 2025
- Newsletter 26/2025 June 29, 2025
- AlphaGenome: Another Incredible AI Tool for Biology June 27, 2025
- Phase 1 Trial of 225Ac-ETN029 for Neuroendocrine Prostate Cancer June 26, 2025